Simplex Trading’s Genmab GMAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.5K Sell
800
-2,400
-75% -$71.9K ﹤0.01% 6721
2025
Q4
$98.6K Sell
3,200
-4,700
-59% -$146K ﹤0.01% 5015
2025
Q3
$242K Sell
7,900
-18,300
-70% -$446K ﹤0.01% 4711
2025
Q2
$541K Sell
26,200
-56,400
-68% -$1.16M ﹤0.01% 3425
2025
Q1
$1.62M Buy
82,600
+78,800
+2,074% +$1.65M ﹤0.01% 2239
2024
Q4
$79K Buy
3,800
+3,600
+1,800% +$79.1K ﹤0.01% 5400
2024
Q3
$4K Buy
200
+100
+100% +$2.67K ﹤0.01% 7717
2024
Q2
$2K Sell
100
-6,700
-99% -$190K ﹤0.01% 8272
2024
Q1
$203K Buy
6,800
+4,000
+143% +$118K ﹤0.01% 4841
2023
Q4
$89K Buy
2,800
+2,400
+600% +$75.4K ﹤0.01% 5502
2023
Q3
$14K Sell
400
-600
-60% -$22.9K ﹤0.01% 6925
2023
Q2
$38K Sell
1,000
-300
-23% -$12K ﹤0.01% 6099
2023
Q1
$49K Sell
1,300
-4,200
-76% -$161K ﹤0.01% 5945
2022
Q4
$233K Buy
+5,500
New +$227K ﹤0.01% 4036
2022
Q3
Sell
-1,000
Closed -$32K 10263
2022
Q2
$32K Buy
1,000
+700
+233% +$22.7K ﹤0.01% 7055
2022
Q1
$10K Sell
300
-300
-50% -$10.3K ﹤0.01% 8858
2021
Q4
$23K Buy
+600
New +$25K ﹤0.01% 8192
2021
Q2
Sell
-1
Closed -$3K 10261
2021
Q1
$3K Buy
+1
New +$38 ﹤0.01% 8362

Other funds holding GMAB

Simplex Trading's GMAB Position: Q3 2025 in Review

Simplex Trading sold out of Genmab (GMAB) in Q3 2025, closing a stake of 5,630 shares — an estimated $137K sold.

Simplex Trading first reported a position in GMAB in Q1 2021 and held it in 14 quarters. The position peaked at $1.24M in Q1 2025. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • Simplex Trading reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
  • Simplex Trading sold 5,630 Genmab shares in Q3 2025, an estimated $137K.
  • Simplex Trading first reported a position in Genmab in Q1 2021 and held it in 14 quarters.
  • Simplex Trading's Genmab position peaked at $1.24M in Q1 2025.
  • 252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.